Video

Mark S. Freedman, HBSc, MSc, MD

Publish date: June 5, 2015

At the 2015 CMSC Annual Meeting, Prof. Mark Freedman discusses recent trial results for teriflunomide.


 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Promoting MS Medication Adherence Through Telehealth
ICYMI Multiple Sclerosis
Variation in Brain Iron Levels in MS and CIS
ICYMI Multiple Sclerosis
Does Education Status Impact MS Risk?
ICYMI Multiple Sclerosis
Factors Linking Optic Neuritis to MS Risk
ICYMI Multiple Sclerosis
When Patients Don’t Respond to Interferon-β
ICYMI Multiple Sclerosis
Life Expectancy and Multiple Sclerosis
ICYMI Multiple Sclerosis
Switching From Natalizumab to Dimethyl Fumarate: Real-World Experience
ICYMI Multiple Sclerosis
Alemtuzumab May Suppress Disease Activity for Four Years
ICYMI Multiple Sclerosis
Daclizumab HYP May Improve Ambulation and Cognition, Compared With Interferon β-1a
ICYMI Multiple Sclerosis
Samuel F. Hunter, MD, PhD
ICYMI Multiple Sclerosis